Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-23
2011-08-23
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S131000
Reexamination Certificate
active
08003641
ABSTRACT:
The invention relates to compounds and methods for treating cell proliferation disorders.
REFERENCES:
patent: 3761477 (1973-09-01), Schwartz et al.
patent: 3868380 (1975-02-01), Molteni et al.
patent: 4010279 (1977-03-01), Griss et al.
patent: 6538960 (2003-03-01), Sabi et al.
patent: 6844367 (2005-01-01), Zhu et al.
patent: 2004/0242572 (2004-12-01), Stenkamp et al.
patent: 2005/0059713 (2005-03-01), Mjalli et al.
patent: 2006/0160800 (2006-07-01), Hangauer, Jr.
patent: 0 463 638 (1992-01-01), None
patent: WO 1992/19208 (1992-11-01), None
patent: WO 96/12473 (1996-05-01), None
patent: WO 99/01127 (1999-01-01), None
patent: WO 01/19788 (2001-03-01), None
patent: WO 01/85726 (2001-11-01), None
patent: WO 02/079197 (2002-10-01), None
patent: WO 03/059903 (2003-07-01), None
patent: WO 03/078404 (2003-09-01), None
patent: WO 03/087057 (2003-10-01), None
patent: WO 03/093297 (2003-11-01), None
patent: WO 2004/011427 (2004-02-01), None
patent: WO 2004/056774 (2004-07-01), None
patent: WO 2005/013914 (2005-02-01), None
patent: WO 2005/032493 (2005-04-01), None
patent: WO 2006/071960 (2006-07-01), None
patent: WO 2007/026920 (2007-03-01), None
patent: WO 2007/095383 (2007-08-01), None
Byrn et al., Solid-State Chemistry of Drugs, Second Edition, 1999, pp. 233-247.
Cain et al., “Potential Antitumor Agents. IX. Bisquaternary Salts”,J. Med. Chem., 11(5):963-966 (1968).
Liechti et al., “Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor”,Eur. J. Med. Chem., 39(1):11-26 (2004).
Million et al., “Inhibition of the EGF-stimulated cellular proliferation of ER 22 cells by hydroxybiphenyl derivatives”,J. Med. Chem., 38(23):4693-4703 (1995).
Zhng et al., “Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs”,Bioorg. Med. Chem. Lett., 14(4):983-987 (2004).
Davidson et al., “Discovery and characterization of a substrate selective p38α inhibitor”, Biochemistry, 43:11658-11671 (2004).
Frame, M.C., “Src in cancer:deregulation and consequences for cell behaviour”,Biochem. Biophys. Acta, 1602:114-130 (2002).
Guo et al., “Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia”,J. Neurosci., 22(14):6208-6217 (2002).
Hadjeri et al., “Antimitotic activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones”.J. Med. Chem., 47:4964-4970 (2004).
Parang et al., “Recent advances in the discovery of Src kinase inhibitors”,Expert Opin. Ther. Patents, 15(9):1183-1207 (2005).
Paul et al., “Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke”,Nat. Med., 7(2):222-227 (2001).
Yu et al., “Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors”, Proc. Natl. Acad. Sci. USA, 96:7697-7704 (1999).
Honma et al.,J. Med. Chem. 26:1499-1504 (1983).
Anderson Rebecca L
Elrifi, Esq. Ivor R.
Erlacher, Esq. Heidi A.
Kinex Pharmaceuticals, LLC
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Compositions and methods of treating cell proliferation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods of treating cell proliferation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods of treating cell proliferation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2787795